Matt Patterson
Chairman chez VOR BIOPHARMA INC.
Fortune : 97 635 $ au 31/03/2024
Profil
Matthew R.
Patterson was the founder and had founded Astellas Gene Therapies, Inc. in 2012, where he held the title of Chairman & Chief Executive Officer from 2018 to 2020.
He currently holds the position of Chairman at Vor Biopharma, Inc. since 2020, Executive Chairman at Iris Medicine, Inc., Executive Chairman at Remix Therapeutics, Inc. since 2021, Director at Gilda's Club New York City, Inc. since 2010, Director at Modis Therapeutics, Inc. since 2018, and Independent Director at 5:01 Acquisition Corp.
since 2020.
In his former positions, Mr. Patterson served as President & Chief Executive Officer at Amicus Therapeutics, Inc. from 2004 to 2010, Chairman at Alliance for Regenerative Medicine from 2015 to 2020, and held the title of Vice President-Commercial Planning at BioMarin Pharmaceutical, Inc. from 1998 to 2004.
He also worked as a Senior Associate-Regulatory Affairs at Genzyme Corp.
from 1993 to 1998 and served as an Entrepreneur-in-Residence at OrbiMed Advisors Private Equity.
Mr. Patterson obtained his undergraduate degree from Bowdoin College in 1993.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VOR BIOPHARMA, INC.
0,06% | 26/03/2024 | 41 196 ( 0,06% ) | 97 635 $ | 31/03/2024 |
-.--% | 14/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Matt Patterson
| Sociétés | Poste | Début |
|---|---|---|
| 501 ACQU | Director/Board Member | 01/10/2020 |
| VOR BIOPHARMA INC. | Chairman | 11/06/2021 |
Gilda's Club New York City, Inc.
 Gilda's Club New York City, Inc. Miscellaneous Commercial ServicesCommercial Services Gilda's Club New York City, Inc. provides support services to cancer patients. Its programs include cancer support for all, offsite program, and programs for children and teens with cancer. The company was founded by Gene Wilder, Joanna Bull, Mandy Patinkin, and Joel Siegel in 1995 and is headquartered in New York, NY. | Director/Board Member | 01/01/2010 |
Modis Therapeutics, Inc.
 Modis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA. | Director/Board Member | 29/10/2018 |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Chairman | 16/03/2021 |
Iris Medicine, Inc.
 Iris Medicine, Inc. Medical/Nursing ServicesHealth Services Iris Medicine, Inc. is engaged in providing healthcare services. The company was founded by Keith Gagnon and Megan Blewett and is headquartered in Palo Alto, CA. | Chairman | - |
Anciens postes connus de Matt Patterson
| Sociétés | Poste | Fin |
|---|---|---|
| AUDENTES THERAPEUTICS, INC. | Chief Executive Officer | 15/01/2020 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Chairman | 01/01/2020 |
| AMICUS THERAPEUTICS, INC. | Chief Executive Officer | 31/12/2010 |
| ░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Matt Patterson
| Bowdoin College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| AMICUS THERAPEUTICS, INC. | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
Gilda's Club New York City, Inc.
Gilda's Club New York City, Inc. Miscellaneous Commercial ServicesCommercial Services Gilda's Club New York City, Inc. provides support services to cancer patients. Its programs include cancer support for all, offsite program, and programs for children and teens with cancer. The company was founded by Gene Wilder, Joanna Bull, Mandy Patinkin, and Joel Siegel in 1995 and is headquartered in New York, NY. | Commercial Services |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Modis Therapeutics, Inc.
Modis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA. | Commercial Services |
Iris Medicine, Inc.
Iris Medicine, Inc. Medical/Nursing ServicesHealth Services Iris Medicine, Inc. is engaged in providing healthcare services. The company was founded by Keith Gagnon and Megan Blewett and is headquartered in Palo Alto, CA. | Health Services |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Health Technology |
5:01 Acquisition Corp.
 5:01 Acquisition Corp. Financial ConglomeratesFinance 5:01 Acquisition Corp. is a blank check emerging growth company that was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on August 31, 2020 and is headquartered in San Francisco, CA. | Finance |
